NV-5138 (C007B-378404)

NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 is used for antidepressant studiesIn VivoNV-5138 is found to be essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h determined following intravenous and oral dosing in rats . NV-5138 (160 mg/kg, po, single dose) rapidly increases levels of phospho-mTOR as well as the downstream targets, phospho-p70S6K1, and phosphor-4EB-P1, in synaptosomal preparations of PFC. NV-5138 (80 mg/kg, po, daily for a total of 7 days) also produces antidepressant effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats weighing 250-260 g. Dosage: 40, 80, 160 mg/kg. Administration: PO, single dose (160 mg/kg) or daily for a total of 7 days (40, 80 mg/kg). Result: Produced antidepressant effects. Animal Model: Male Sprague–Dawley (SD) rats weighed 250-400 g . Dosage: 1 mg/kg, 5 mg/kg ( Pharmacokinetic Design ). Administration: I.V at 1 mg/kg and PO at 5 mg/kg. Result: Essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h.Form:SolidIC50& Target:mTORC1. Specification: ≥98.0% Molecular Formula: C7H13F2NO2 Molecular Weight: 181.18 PubChem CID: 129050791 Isomeric SMILES: CC(C)(C[C@@H](C(=O)O)N)C(F)F

UPC:

51142310

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

N646865-10mg

CAS:

2095886-80-7

Product Size:

10mg